ArticleMedical science monitor : international medical journal of experimental and clinical research2015
A Biocompatible Reconstituted High-Density Lipoprotein Nano-System as a Probe for Lung Cancer Detection.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Near-Infrared Fluorescence Tumor-Targeted Imaging in Lung Cancer: A Systematic Review.Life (Basel, Switzerland) · 2022Review
- Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers.Nano-micro letters · 2021Review
- Sterically stabilized recombined HDL composed of modified apolipoprotein A-I for efficient targeting toward glioma cells.Drug delivery · 2020Article
- Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications.Chemical Society reviews · 2018Review
- Reconstituted HDL: Drug Delivery Platform for Overcoming Biological Barriers to Cancer Therapy.Frontiers in pharmacology · 2018Review
- Anti-EGFR antibody conjugated silica nanoparticles as probes for lung cancer detection.Experimental and therapeutic medicine · 2017Article
- Tumor-targeting templated silica nanoparticles as a dual-drug delivery system for anti-angiogenic ovarian cancer therapy.Experimental and therapeutic medicine · 2017Article
- Biomimetic strategies for targeted nanoparticle delivery.Bioengineering & translational medicine · 2016Review
- Targeting SR-BI for Cancer Diagnostics, Imaging and Therapy.Frontiers in pharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly detection of cancer is critical and is expected to contribute significantly to the success of cancer therapy and improvement of patient survival rates. MATERIAL AND
methodsA biocompatible, reconstituted, high-density lipoprotein (rHDL)-based nano-system containing calcium carbonate and near-infrared fluorescence dye (NIRF), methylene blue (MB), was fabricated and characterized by particle size, zeta potential, and morphology observation. The safety profile was confirmed by bovine serum albumin (BSA) challenge assay, hemolysis test, MTT assay, and in vivo long-term toxicity assay. The tumor targetability was assessed by cellular uptake, competitive inhibition experiments, and in vivo imaging assay.
resultsThe self-assembled rHDL/MB/CCPs exhibited desirable and homogenous particle size, neutral surface charges, high bovine serum albumin stability, low hemolytic activity, and negligible cytotoxicity in vitro. The results obtained from confocal scanning laser microscopy and flow cytometry indicated that SR-BI coating exerted tumor-targeting function, which induced high and specific cellular uptake of rHDL/MB/CCPs. In vivo investigation in an A549 tumor xenografts-bearing mouse model revealed that rHDL/MB/CCPs possessed strong tumor targetability.
conclusionsrHDL/MB/CCPs could be a safe tumor-targeting probe for cancer detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.